A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell-surface proteins on target cells

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy against refractory B-cell malignancies shows excellent therapeutic effects. However, there are some obstacles to be overcome in this treatment. Since current CAR-T cells target a single cell-surface protein on tumor cells, the CAR-T cells also...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoyama, Satoru, Yasuda, Shunichiro, Li, Huixin, Watanabe, Daisuke, Umezawa, Yoshihiro, Okada, Keigo, Nogami, Ayako, Miura, Osamu, Kawamata, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846940/
https://www.ncbi.nlm.nih.gov/pubmed/35119085
http://dx.doi.org/10.3892/ijmm.2022.5097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846940/
https://www.ncbi.nlm.nih.gov/pubmed/35119085
http://dx.doi.org/10.3892/ijmm.2022.5097

Ejemplares similares